Abstracts

INVESTIGATION OF CLASSIC AND HIV-RELATED FACTORS FOR HEPATIC STEATOSIS AMONG PWID

Numerous studies show a link between visceral adiposity and metabolic disorders. Fatty liver is an established risk factor for cirrhosis and liver cancer and is increasing among aging persons living with HIV (PWH).  We investigated the prevalence and correlates of hepatic steatosis, assessed non-invasively by elastography with controlled attenuation parameter (CAP), in a community cohort of…

HIV VIRAL BLIPS IN ADULTS TREATED WITH InSTI-BASED REGIMENS THROUGH 144 WEEKS

The clinical impact of viral blips on virologic failure and resistance development depends on the resistance barrier and forgiveness of the regimen. Here, we investigated the blip frequency and virologic outcomes of those experiencing blips among treatment-naïve people with HIV (PWH) initiating therapy on bictegravir (B)/emtricitabine (F)/tenofovir alafenamide (TAF), dolutegravir (DTG)/abacavir (ABC)/lamivudine (3TC), or DTG…

RESISTANCE TO INTEGRASE STRAND TRANSFER INHIBITORS AMONG MSM IN THE US: HPTN 078

Increasing viral suppression with antiretroviral therapy (ART) is a critical step in curbing the HIV epidemic. Integrase strand transfer inhibitor (INSTI)-based ART regimens are now recommended for first-line ART in the United States (US), but pre-treatment resistance testing does not routinely include testing for INSTI resistance. The HIV Prevention Trials Network (HPTN) 078 study evaluated…

EXPANDED SPECTRUM OF ANTIRETROVIRAL-SELECTED HIV-2 MUTATIONS

There has been no systematic review of treatment-selected HIV-2 mutations. We reviewed published HIV-2 sequences to identify previously unreported ARV-selected HIV-2 mutations. Prevalence of each PR, RT, and IN mutation was determined by ARV status. Nonpolymorphic mutations (NPMs) were defined as occurring in <1% of ARV-naïve persons. Nonpolymorphic treatment selected mutations (NP-TSMs) were defined as…

HIV DRUG RESISTANCE ACROSS ANATOMICAL TISSUES

HIV drug resistance can be an obstacle to successful antiretroviral therapy (ART), but the vast majority of studies on drug resistance have focused on studying blood. Here, we present evidence of drug resistance across multiple tissues in two persons with HIV. Last Gift study participant 3 (LG03) was a 72-year-old man with HIV and metastatic pancreatic…

PHENOTYPIC DORAVIRINE SUSCEPTIBILITY AFTER NNRTI EXPOSURE IN THE PRESTIGIO REGISTRY

Doravirine (DOR) is an NNRTI recently licensed for first-line ART showing superior genetic barrier to resistance and partial cross-resistance with older NNRTI. We investigated susceptibility to DOR in patients with documented 4-class drug-resistance to NRTI, NNRTI, PI, INSTI (4CR), enrolled in the Italian PRESTIGIO Registry. Recombinant HIV-1 expressing patient derived PR-RT were generated from plasma…